101. EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
- Author
-
Liu-Liu Yuan, Ming-Ming Liu, Yuan-Zheng Xia, Rui-Fang Dong, Jing Bian, Yi-Ting Xu, Miao-Lin Zhu, and Ling-Yi Kong
- Subjects
0301 basic medicine ,Lung Neoplasms ,medicine.medical_treatment ,Antineoplastic Agents ,Targeted therapy ,03 medical and health sciences ,T790M ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,medicine ,Animals ,Humans ,Epidermal growth factor receptor ,Lung cancer ,Protein Kinase Inhibitors ,Pharmacology ,biology ,Kinase ,Mechanism (biology) ,business.industry ,Cancer ,medicine.disease ,Precision medicine ,respiratory tract diseases ,ErbB Receptors ,030104 developmental biology ,Drug Resistance, Neoplasm ,030220 oncology & carcinogenesis ,Mutation ,Cancer research ,biology.protein ,business - Abstract
With the development of precision medicine, molecular targeted therapy has been widely used in the field of cancer, especially in non-small-cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) is a well-recognized and effective target for NSCLC therapies, targeted EGFR therapy with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) has achieved ideal clinical efficacy in recent years. Unfortunately, resistance to EGFR-TKIs inevitably occurs due to various mechanisms after a period of therapy. EGFR mutations, such as T790M and C797S, are the most common mechanism of EGFR-TKI resistance. Here, we discuss the mechanisms of EGFR-TKIs resistance induced by secondary EGFR mutations, highlight the development of targeted drugs to overcome EGFR mutation-mediated resistance, and predict the promising directions for development of novel candidates.
- Published
- 2021
- Full Text
- View/download PDF